tert-butyl 1-(4-(5-(4-phenyl-5-(trifluoromethyl)thiophen-2-yl)-1,2,4-oxadiazol-3-yl)benzyl)azetidine-3-carboxylate | 1236144-81-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: tert-butyl 1-(4-(5-(4-phenyl-5-(trifluoromethyl)thiophen-2-yl)-1,2,4-oxadiazol-3-yl)benzyl)azetidine-3-carboxylate
• 英文别名: tert-butyl 1-[[4-[5-[4-phenyl-5-(trifluoromethyl)thiophen-2-yl]-1,2,4-oxadiazol-3-yl]phenyl]methyl]azetidine-3-carboxylate
• CAS: 1236144-81-2
• 化学式: C₂₈H₂₆F₃N₃O₃S
• 分子量: 541.594
• InChiKey: FWDZTRGANJEROT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.2
• 重原子数：
  38
• 可旋转键数：
  8
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.32
• 拓扑面积：
  96.7
• 氢给体数：
  0
• 氢受体数：
  10

反应信息

• 作为反应物：
  描述：

  tert-butyl 1-(4-(5-(4-phenyl-5-(trifluoromethyl)thiophen-2-yl)-1,2,4-oxadiazol-3-yl)benzyl)azetidine-3-carboxylate 在 盐酸 、 水 、 甲醇 作用下， 以 三氟乙酸 、 甲醇 为溶剂， 反应 33.5h， 以afforded 1-(4-(5-(4-phenyl-5-(trifluoromethyl)thiophen-2-yl)-1,2,4-oxadiazol-3-yl)benzyl)-azetidine-3-carboxylic acid (345 mg, 0.707 mmol, 74% yield) as a white powder的产率得到1-(4-(5-(4-phenyl-5-(trifluoromethyl)thiophen-2-yl)-1,2,4-oxadiazol-3-yl)benzyl)azetidine-3-carboxylic acid
  参考文献：
  名称：

  SUBSTITUTED HETEROCYCLIC COMPOUNDS

  摘要：

  本发明涉及式（I）的化合物或其药学上可接受的盐，其中Q为R1为环烷基，杂环芳基或杂环基，每个基可选地用1到5个取代基独立地选择自C1到C6烷基，C1到C4卤代烷基，-OR4和/或卤素取代;R2，R3，R4和n在此定义。本发明还涉及将这些化合物用作选择性G蛋白偶联受体S1P1的激动剂的方法，以及包含这些化合物的制药组合物。这些化合物在多种治疗领域中有用，例如血管疾病和自身免疫疾病的治疗，可用于治疗、预防或减缓疾病或障碍的进展。

  公开号：

  US20120022041A1
• 作为产物：
  描述：

  4-苯基-5-(三氟甲基)噻吩-2-羧基 酸 在 四丁基氟化铵 、 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 N,N-二异丙基乙胺 作用下， 以 四氢呋喃 、 N,N-二甲基甲酰胺 、 乙腈 为溶剂， 反应 90.0h， 生成 tert-butyl 1-(4-(5-(4-phenyl-5-(trifluoromethyl)thiophen-2-yl)-1,2,4-oxadiazol-3-yl)benzyl)azetidine-3-carboxylate
  参考文献：
  名称：

  [EN] SUBSTITUTED OXADIAZOLE DERIVATIVES AS S1P AGONISTS IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISEASES
  [FR] DÉRIVÉS D'OXADIAZOLE SUBSTITUÉS COMME AGONISTES DE S1P DANS LE TRAITEMENT DE MALADIES AUTO-IMMUNES ET INFLAMMATOIRES

  摘要：

  [00180] 公开了公式(I)的化合物或其药用可接受的盐，其中Q是或R1是环烷基、杂芳基或杂环烷基，每个环烷基、杂芳基或杂环烷基可选地被一个到五个独立选自C1至C6烷基、C1至C4卤代烷基、-OR4和/或卤素的取代基所取代；R2、R3、R4和n的定义如本文中所述。还公开了使用这些化合物作为G蛋白偶联受体S1P1的选择性激动剂的方法，以及包含这些化合物的药物组合物。这些化合物在治疗、预防或减缓多种治疗领域，如血管疾病和自身免疫疾病的疾病或障碍的进展方面是有用的。

  公开号：

  WO2010085582A1

文献信息

• [EN] PYRAZOLE-I, 2, 4 -OXAD IAZOLE DERIVATIVES AS S.PHING0SINE-1-PH0SPHATE AGONISTS<br/>[FR] DÉRIVÉS DE PYRAZOLE-1,2,4-OXADIAZOLE EN TANT QU'AGONISTES DE SPHINGOSINE-1-PHOSPHATE
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2010085584A1

  公开（公告）日：2010-07-29

  Disclosed are compounds of Formula (I) or a pharmaceutically acceptable salt thereof, wherein: n is zero or an integer selected from 1 through 4; R1 is cycloalkyl, aryl, heteroaryl, or heterocyclyl, each optionally substituted with one to five substituents independently selected from C1 to C6 alkyl, C1 to C4 haloalkyl, benzyl, OR4, and/or halogen; and R2, R3, R4, and n are defined herein. Also disclosed are methods of using such compounds as selective agonists for G protein-coupled receptor S1P1, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.

  公开的是Formula (I)或其药学上可接受的盐的化合物，其中：n为零或选自1至4的整数；R1为环烷基、芳基、杂芳基或杂环烷基，每个可选地用从C1到C6烷基、C1到C4卤代烷基、苄基、OR4和/或卤素中独立选择的一个到五个取代基取代；R2、R3、R4和n在此处有定义。还公开了将这些化合物用作G蛋白偶联受体S1P1的选择性激动剂的方法，以及包含这些化合物的药物组合物。这些化合物在治疗、预防或减缓多种治疗领域的疾病或疾病的进展方面是有用的，例如自身免疫疾病和血管疾病。
• SUBSTITUTED PYRAZOLE COMPOUNDS
  申请人：Dyckman Alaric J.

  公开号：US20110275610A1

  公开（公告）日：2011-11-10

  Disclosed are compounds of Formula (I) or a pharmaceutically acceptable salt thereof, wherein: n is zero or an integer selected from 1 through 4; R 1 is cycloalkyl, aryl, heteroaryl, or heterocyclyl, each optionally substituted with one to five substituents independently selected from C 1 to C 6 alkyl, C 1 to C 4 haloalkyl, benzyl, —OR 4 , and/or halogen; and R 2 , R 3 , R 4 , and n are defined herein. Also disclosed are methods of using such compounds as selective agonists for G protein-coupled receptor S1P 1 , and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.

  本发明涉及式（I）化合物或其药学上可接受的盐，其中：n为零或选自1至4的整数；R1为环烷基、芳基、杂芳基或杂环基，每个基团可选地被1至5个取自C1至C6烷基、C1至C4卤代烷基、苄基、—OR4和/或卤素的基团独立地取代；并且R2、R3、R4和n如本文所定义。本发明还涉及使用这些化合物作为G蛋白偶联受体S1P1的选择性激动剂的方法，以及包括这些化合物的制药组合物。这些化合物在多种治疗领域中用于治疗、预防或减缓疾病或障碍的进展，如自身免疫性疾病和血管疾病。
• SUBSTITUTED ISOXAZOLE COMPOUNDS
  申请人：Watterson Scott Hunter

  公开号：US20110300165A1

  公开（公告）日：2011-12-08

  Disclosed are compounds of Formula (I) or pharmaceutically acceptable salts thereof, wherein Q is R 1 is alkyl or aryl, said aryl optionally substituted with one to five substituents independently selected from C 1 to C 6 alkyl, C 1 to C 4 haloalkyl, —OR 4 , and/or halogen; and R 2 , R 3 , R 4 , and n are defined herein. Also disclosed are methods of using such compounds as selective agonists for G protein-coupled receptor S1P 1 , and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.

  本发明涉及公式（I）化合物或其药学上可接受的盐，其中Q是R1是烷基或芳基，所述芳基可选择性地被1到5个独立选择的取代基所取代，所述取代基选择自C1到C6烷基，C1到C4卤代烷基，-OR4和/或卤素; R2、R3、R4和n在此被定义。本发明还涉及使用这些化合物作为G蛋白偶联受体S1P1的选择性激动剂的方法，以及包含这些化合物的制药组合物。这些化合物在多种治疗领域中有用，例如自身免疫性疾病和血管疾病的治疗、预防或减缓疾病或障碍的进展。
• SUBSTITUTED HETEROCYCLIC COMPOUNDS
  申请人：Pitts William J.

  公开号：US20120022041A1

  公开（公告）日：2012-01-26

  Disclosed are compounds of Formula (I) or pharmaceutically acceptable salts thereof, wherein Q is R 1 is cycloalkyl, heteroaryl, or heterocyclyl, each optionally substituted with one to five substituents independently selected from C 1 to C 6 alkyl, C 1 to C 4 haloalkyl, —OR 4 , and/or halogen; and R 2 , R 3 , R 4 , and n are defined herein. Also disclosed are methods of using such compounds as selective agonists for G protein-coupled receptor S1P 1 , and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as vascular disease and autoimmune diseases.

  本发明涉及式（I）的化合物或其药学上可接受的盐，其中Q为R1为环烷基，杂环芳基或杂环基，每个基可选地用1到5个取代基独立地选择自C1到C6烷基，C1到C4卤代烷基，-OR4和/或卤素取代;R2，R3，R4和n在此定义。本发明还涉及将这些化合物用作选择性G蛋白偶联受体S1P1的激动剂的方法，以及包含这些化合物的制药组合物。这些化合物在多种治疗领域中有用，例如血管疾病和自身免疫疾病的治疗，可用于治疗、预防或减缓疾病或障碍的进展。
• Substituted pyrazole compounds
  申请人：Dyckman Alaric J.

  公开号：US08389509B2

  公开（公告）日：2013-03-05

  Disclosed are compounds of Formula (I) or a pharmaceutically acceptable salt thereof, wherein: n is zero or an integer selected from 1 through 4; R1 is cycloalkyl, aryl, heteroaryl, or heterocyclyl, each optionally substituted with one to five substituents independently selected from C1 to C6 alkyl, C1 to C4 haloalkyl, benzyl, —OR4, and/or halogen; and R2, R3, R4, and n are defined herein. Also disclosed are methods of using such compounds as selective agonists for G protein-coupled receptor S1P1, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.

  本发明涉及式(I)化合物或其药学上可接受的盐，其中：n为零或选自1至4的整数；R1为环烷基、芳基、杂芳基或杂环烷基，每个基团可选择地被一到五个取自C1至C6烷基、C1至C4卤代烷基、苯甲基、—OR4和/或卤素的基团独立地取代；R2、R3、R4和n的定义如本文所述。本发明还涉及使用这些化合物作为选择性G蛋白偶联受体S1P1激动剂的方法，以及包含这些化合物的药物组合物。这些化合物在多种治疗领域中有用，例如自身免疫性疾病和血管疾病的治疗、预防或减缓疾病或障碍的进展。